Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC
Abstract Chemoradiotherapy (CRT) followed by durvalumab is standard for unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). This study assesses how CRT alters the T-cell receptor (TCR) repertoire in CD8 + PD-1 + T-cells and its impact on clinical outcomes. This prospective study, co...
Saved in:
Main Authors: | Masayuki Shirasawa, Tatsuya Yoshida, Takaji Matsutani, Yuki Takeyasu, Naoko Goto, Shigehiro Yagishita, Shigehisa Kitano, Hiroaki Kuroda, Toyoaki Hida, Takayasu Kurata, Yuichiro Ohe |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | npj Precision Oncology |
Online Access: | https://doi.org/10.1038/s41698-024-00781-w |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Human TCR repertoire in cancer
by: Lin Chen, et al.
Published: (2024-09-01) -
Unravelling the TCRβ repertoire: a key to unlocking the immunopathogenesis and precision medicine in SLE
by: Qiao Zhou, et al.
Published: (2025-01-01) -
Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer
by: Jiahao Zhang, et al.
Published: (2025-01-01) -
Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120)
by: Mauro Zukin, et al.
Published: (2025-01-01) -
An Entropy Model of Credit Risk Contagion in the CRT Market
by: Tingqiang Chen, et al.
Published: (2015-01-01)